UPLOAD Filing
Processa Pharmaceuticals, Inc.
Date: Aug. 6, 2025 · CIK: 0001533743 · Accession: 0000000000-25-008277
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39531
Letter
Re: Processa Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 31, 2025 File No. 001-39531 Dear Russell Skibsted:
August 6, 2025
Russell Skibsted Chief Financial Officer Processa Pharmaceuticals, Inc. 601 21st Street, Suite 300 Vero Beach, FL, 32960
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A General
1. Please revise the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 or Joe McCann at 202-551-6262 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 6, 2025 Russell Skibsted Chief Financial Officer Processa Pharmaceuticals, Inc. 601 21st Street, Suite 300 Vero Beach, FL, 32960 Re: Processa Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 31, 2025 File No. 001-39531 Dear Russell Skibsted: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Preliminary Proxy Statement on Schedule 14A General 1. Please revise the preliminary proxy statement to fill in the number of authorized shares in proposal number 1 and the reverse stock split ratios in proposal number 2. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 or Joe McCann at 202-551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>